216 related articles for article (PubMed ID: 24378646)
1. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
Cardozo EF; Luo R; Piovoso MJ; Zurakowski R
J Theor Biol; 2014 Mar; 345():61-9. PubMed ID: 24378646
[TBL] [Abstract][Full Text] [Related]
2. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
[TBL] [Abstract][Full Text] [Related]
4. Influence of raltegravir intensification on viral load and 2-LTR dynamics in HIV patients on suppressive antiretroviral therapy.
Wang X; Mink G; Lin D; Song X; Rong L
J Theor Biol; 2017 Mar; 416():16-27. PubMed ID: 28025011
[TBL] [Abstract][Full Text] [Related]
5. Modelling HIV-1 2-LTR dynamics following raltegravir intensification.
Luo R; Cardozo EF; Piovoso MJ; Wu H; Buzon MJ; Martinez-Picado J; Zurakowski R
J R Soc Interface; 2013 Jul; 10(84):20130186. PubMed ID: 23658114
[TBL] [Abstract][Full Text] [Related]
6. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
McMahon D; Jones J; Wiegand A; Gange SJ; Kearney M; Palmer S; McNulty S; Metcalf JA; Acosta E; Rehm C; Coffin JM; Mellors JW; Maldarelli F
Clin Infect Dis; 2010 Mar; 50(6):912-9. PubMed ID: 20156060
[TBL] [Abstract][Full Text] [Related]
7. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
8. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
Hatano H; Strain MC; Scherzer R; Bacchetti P; Wentworth D; Hoh R; Martin JN; McCune JM; Neaton JD; Tracy RP; Hsue PY; Richman DD; Deeks SG
J Infect Dis; 2013 Nov; 208(9):1436-42. PubMed ID: 23975885
[TBL] [Abstract][Full Text] [Related]
9. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
Gandhi RT; Zheng L; Bosch RJ; Chan ES; Margolis DM; Read S; Kallungal B; Palmer S; Medvik K; Lederman MM; Alatrakchi N; Jacobson JM; Wiegand A; Kearney M; Coffin JM; Mellors JW; Eron JJ;
PLoS Med; 2010 Aug; 7(8):. PubMed ID: 20711481
[TBL] [Abstract][Full Text] [Related]
10. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
Besson GJ; McMahon D; Maldarelli F; Mellors JW
Clin Infect Dis; 2012 Feb; 54(3):451-3. PubMed ID: 22016501
[No Abstract] [Full Text] [Related]
11. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
[TBL] [Abstract][Full Text] [Related]
12. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
13. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
Delaugerre C; Charreau I; Braun J; Néré ML; de Castro N; Yeni P; Ghosn J; Aboulker JP; Molina JM; Simon F;
AIDS; 2010 Sep; 24(15):2391-5. PubMed ID: 20683319
[TBL] [Abstract][Full Text] [Related]
14. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Martinez-Picado J; Zurakowski R; Buzón MJ; Stevenson M
Retrovirology; 2018 Jan; 15(1):15. PubMed ID: 29378611
[TBL] [Abstract][Full Text] [Related]
15. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
[TBL] [Abstract][Full Text] [Related]
16. Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patients.
Bona R; Baroncelli S; D'Ettorre G; Andreotti M; Ceccarelli G; Filati P; Leone P; Blasi M; Michelini Z; Galluzzo CM; Mallano A; Vullo V; Cara A
AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1365-9. PubMed ID: 23802629
[TBL] [Abstract][Full Text] [Related]
17. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of CD8 T-cell activation after discontinuation of HIV treatment intensification.
Massanella M; Esteve A; Buzón MJ; Llibre JM; Puertas MC; Gatell JM; Domingo P; Stevenson M; Clotet B; Martinez-Picado J; Blanco J;
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):152-60. PubMed ID: 23392458
[TBL] [Abstract][Full Text] [Related]
19. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
[TBL] [Abstract][Full Text] [Related]
20. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
